Champions Oncology Stock Analysis
| CSBR Stock | USD 10.26 0.68 7.10% |
Champions Oncology is overvalued with Real Value of 7.7 and Target Price of 8.0. The main objective of Champions Oncology stock analysis is to determine its intrinsic value, which is an estimate of what Champions Oncology is worth, separate from its market price. There are two main types of Champions Oncology's stock analysis: fundamental analysis and technical analysis.
The Champions Oncology stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Champions Oncology is usually not traded on Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, National Mourning Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day. Champions Stock trading window is adjusted to America/New York timezone.
Champions |
Champions Stock Analysis Notes
About 26.0% of the company shares are held by company insiders. The company has Price/Earnings (P/E) ratio of 220.0. Champions Oncology recorded a loss per share of 0.05. The entity had not issued any dividends in recent years. The firm had 1:12 split on the 12th of August 2015. Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey. Champions Oncolog operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 230 people. For more info on Champions Oncology please contact Ronnie MD at 201 808 8400 or go to https://www.championsoncology.com.Champions Oncology Investment Alerts
| Champions Oncology is way too risky over 90 days horizon | |
| Champions Oncology appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 50.16 M. Net Loss for the year was (7.28 M) with profit before overhead, payroll, taxes, and interest of 23.97 M. | |
| Champions Oncology currently holds about 8.06 M in cash with (6.14 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.6. | |
| Champions Oncology has a frail financial position based on the latest SEC disclosures | |
| Roughly 26.0% of the company shares are held by company insiders | |
| Latest headline from simplywall.st: Champions Oncology pulls back 16 percent this week, but still delivers shareholders notable 57 percent return over 1 year |
Champions Oncology Upcoming and Recent Events
| 20th of March 2024 Upcoming Quarterly Report | View | |
| 22nd of July 2024 Next Financial Report | View | |
| 31st of January 2024 Next Fiscal Quarter End | View | |
| 22nd of July 2024 Next Fiscal Year End | View | |
| 31st of October 2023 Last Quarter Report | View | |
| 30th of April 2023 Last Financial Announcement | View |
Champions Largest EPS Surprises
Earnings surprises can significantly impact Champions Oncology's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2020-12-14 | 2020-10-31 | 0.0067 | 1.0E-4 | -0.0066 | 98 | ||
2022-12-13 | 2022-10-31 | -0.01 | -0.0012 | 0.0088 | 88 | ||
2021-12-13 | 2021-10-31 | 0.01 | 0.02 | 0.01 | 100 |
Champions Oncology Environmental, Social, and Governance (ESG) Scores
Champions Oncology's ESG score is a quantitative measure that evaluates Champions Oncology's performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Champions Oncology's operations that may have significant financial implications and affect Champions Oncology's stock price as well as guide investors towards more socially responsible investments.
Champions Stock Institutional Investors
Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | State Street Corp | 2024-12-31 | 26.6 K | Bank Of America Corp | 2024-12-31 | 25.3 K | Cambridge Invest Research Advisors, Inc. | 2024-12-31 | 12.3 K | Mesirow Fin Investmt Mgmt Intl Equity | 2024-12-31 | 12 K | Susquehanna International Group, Llp | 2024-12-31 | 11.5 K | Virtu Financial Llc | 2024-12-31 | 11.1 K | Millennium Management Llc | 2024-12-31 | 10.9 K | Tower Research Capital Llc | 2024-12-31 | 1.6 K | Capital Advisors, Ltd. Llc | 2024-12-31 | 48.0 | Battery Management Corp | 2024-12-31 | 2.4 M | Nea Management Company, Llc | 2024-12-31 | 1.7 M |
Champions Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 140.55 M.Champions Profitablity
The company has Profit Margin (PM) of (0.01) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of 0.05 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.05.| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.25) | (0.27) | |
| Return On Capital Employed | (1.44) | (1.51) | |
| Return On Assets | (0.25) | (0.26) | |
| Return On Equity | 4.40 | 4.62 |
Management Efficiency
As of 02/27/2025, Return On Equity is likely to grow to 4.62, while Return On Tangible Assets are likely to drop (0.27). At this time, Champions Oncology's Total Assets are relatively stable compared to the past year. As of 02/27/2025, Non Current Assets Total is likely to grow to about 15.1 M, while Intangible Assets are likely to drop slightly above 650.6 K. Champions Oncology's management efficiency ratios could be used to measure how well Champions Oncology manages its routine affairs as well as how well it operates its assets and liabilities.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (0.16) | (0.15) | |
| Tangible Book Value Per Share | (0.19) | (0.18) | |
| Enterprise Value Over EBITDA | (12.56) | (11.93) | |
| Price Book Value Ratio | (39.71) | (41.69) | |
| Enterprise Value Multiple | (12.56) | (11.93) | |
| Price Fair Value | (39.71) | (41.69) | |
| Enterprise Value | 63.5 M | 44.4 M |
Champions Oncology's management has consistently demonstrated strong leadership, driving both financial growth and operational excellence. By analyzing current market trends and future growth opportunities, we assess the stock's true value and potential for investors.
Technical Drivers
As of the 27th of February, Champions Oncology shows the risk adjusted performance of 0.1776, and Mean Deviation of 4.72. Champions Oncology technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Champions Oncology coefficient of variation, as well as the relationship between the treynor ratio and semi variance to decide if Champions Oncology is priced correctly, providing market reflects its regular price of 10.26 per share. Given that Champions Oncology has jensen alpha of 1.41, we suggest you to validate Champions Oncology's prevailing market performance to make sure the company can sustain itself at a future point.Champions Oncology Price Movement Analysis
The output start index for this execution was nineteen with a total number of output elements of fourty-two. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Champions Oncology middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Champions Oncology. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Champions Oncology Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Champions Oncology insiders, such as employees or executives, is commonly permitted as long as it does not rely on Champions Oncology's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Champions Oncology insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Champions Oncology Outstanding Bonds
Champions Oncology issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Champions Oncology uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Champions bonds can be classified according to their maturity, which is the date when Champions Oncology has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Champions Oncology Predictive Daily Indicators
Champions Oncology intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Champions Oncology stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Champions Oncology Corporate Filings
| 14th of February 2025 Other Reports | ViewVerify | |
10Q | 16th of December 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
8K | 11th of December 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 18th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
F4 | 1st of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 30th of October 2024 Other Reports | ViewVerify | |
8K | 15th of October 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Champions Oncology Forecast Models
Champions Oncology's time-series forecasting models are one of many Champions Oncology's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Champions Oncology's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Champions Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Champions Oncology prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Champions shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Champions Oncology. By using and applying Champions Stock analysis, traders can create a robust methodology for identifying Champions entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (0.17) | (0.18) | |
| Operating Profit Margin | (0.17) | (0.18) | |
| Net Loss | (0.17) | (0.18) | |
| Gross Profit Margin | 0.48 | 0.53 |
Current Champions Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Champions analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Champions analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Advice | # of Analysts | |
| 8.0 | Strong Buy | 1 | Odds |
Most Champions analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Champions stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Champions Oncology, talking to its executives and customers, or listening to Champions conference calls.
Champions Stock Analysis Indicators
Champions Oncology stock analysis indicators help investors evaluate how Champions Oncology stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Champions Oncology shares will generate the highest return on investment. By understating and applying Champions Oncology stock analysis, traders can identify Champions Oncology position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 10.1 M | |
| Common Stock Shares Outstanding | 13.5 M | |
| Total Stockholder Equity | -1.9 M | |
| Tax Provision | -32 K | |
| Quarterly Earnings Growth Y O Y | -0.286 | |
| Property Plant And Equipment Net | 12 M | |
| Cash And Short Term Investments | 2.6 M | |
| Cash | 2.6 M | |
| Accounts Payable | 5.8 M | |
| Net Debt | 4.8 M | |
| 50 Day M A | 9.5142 | |
| Total Current Liabilities | 21.5 M | |
| Other Operating Expenses | 57.5 M | |
| Non Current Assets Total | 12.5 M | |
| Forward Price Earnings | 22.8833 | |
| Non Currrent Assets Other | 185 K | |
| Stock Based Compensation | 1.1 M |
Additional Tools for Champions Stock Analysis
When running Champions Oncology's price analysis, check to measure Champions Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Champions Oncology is operating at the current time. Most of Champions Oncology's value examination focuses on studying past and present price action to predict the probability of Champions Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Champions Oncology's price. Additionally, you may evaluate how the addition of Champions Oncology to your portfolios can decrease your overall portfolio volatility.